A Study of EOS301984 in Adult Participants with Advanced Solid Tumors

2023-503844-14-00 Protocol APT-008 Human pharmacology (Phase I) - First administration to humans Ongoing, recruitment ended

Start 13 Jun 2023 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 7 sites · Protocol APT-008

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruitment ended
Participants planned 84
Countries 1
Sites 7

Advanced Solid Tumors

Key facts

Sponsor
iTeos Belgium
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
13 Jun 2023 → ongoing
Decision date (initial)
2023-05-08
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced Solid Tumors

VersionLevelCodeTermSystem organ class
21.1 LLT 10065252 Solid tumor 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

iTeos Belgium

Sponsor organisation
iTeos Belgium
Address
Rue Des Freres Wright 29/3
City
Charleroi
Postcode
6041
Country
Belgium

Scientific contact point

Organisation
Iteos Therapeutics
Contact name
Iteos Clinical Trial Information

Public contact point

Organisation
Iteos Therapeutics
Contact name
Iteos Clinical Trial Information

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruitment ended 84 7
Rest of world 0

Investigational sites

Belgium

7 sites · Ongoing, recruitment ended
Gasthuiszusters Antwerpen
Medical Oncology, Oosterveldlaan 24, 2610, Antwerp
Cliniques Universitaires Saint-Luc
Medical Oncology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe
Universitair Ziekenhuis Gent
Medical Oncolgy, Corneel Heymanslaan 10, 9000, Gent
Centre hospitalier universitaire de Liege
Medical Oncology, Avenue De L'hopital 1, 4000, Liege
Institut Jules Bordet
Medical Oncology, Mijlenmeersstraat 90, 1070, Brussels
Jessa Ziekenhuis
Medical Oncology, Stadsomvaart 11, 3500, Hasselt
Grand Hopital De Charleroi
Medical Oncology, Rue Du Campus Des Viviers 1, 6060, Charleroi

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2023-06-13 2023-07-07 2025-07-03

Application history

8 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-03-27 Belgium Acceptable with conditions
2023-05-03
2023-05-08
2 SUBSTANTIAL MODIFICATION SM-1 2023-05-31 Belgium Acceptable
2023-06-09
2023-06-19
3 SUBSTANTIAL MODIFICATION SM-2 2023-10-20 Belgium Acceptable
2023-12-12
2023-12-18
4 SUBSTANTIAL MODIFICATION SM-3 2023-12-22 Belgium Acceptable 2024-02-13
5 SUBSTANTIAL MODIFICATION SM-4 2024-05-13 Belgium Acceptable with conditions
2024-06-20
2024-06-20
6 SUBSTANTIAL MODIFICATION SM-5 2024-07-15 Belgium Acceptable
2024-08-02
2024-08-02
7 SUBSTANTIAL MODIFICATION SM-6 2024-12-05 Belgium Acceptable
2025-02-07
2025-02-07
8 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-26 Belgium Acceptable
2025-02-07
2025-12-26